胰高糖素样肽-1受体激动剂周制剂的中国证据  

作　　者：李琳 李全民 

机构地区：[1]解放军火箭军特色医学中心内分泌科,北京100085

出　　处：《药品评价》2020年第S01期33-37,共5页Drug Evaluation

摘　　要：胰高糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonists,GLP-1 RA)是2型糖尿病治疗领域的一类重要新型降糖药,随着2型糖尿病治疗理念的不断发展和循证证据的不断积累,GLP-1 RA在2型糖尿病治疗中的地位不断提升。GLP-1 RA周制剂的出现因为可以减少注射次数,提高患者依从性,得到了越来越多临床医生及患者的认可。各种GLP-1 RA周制剂研发后在中国进行了一系列临床试验,并陆续上市,目前在中国上市的GLP-1 RA周制剂主要有艾塞那肽微球、度拉糖肽、聚乙二醇洛塞那肽。本文将对以上三种GLP-1 RA周制剂的疗效及安全性问题的中国证据进行回顾总结。Glucagon-like peptide-1 receptor agonists(GLP-1 RA)is an important new class of antidiabetic drugs in the field of type 2 diabetes(T2DM)treatment.With the development of concept of treatment with T2DM and accumulation of scientific evidence,GLP-1 RA's status in the treatment of T2DM continues to increase.GLP-1 RA weekly preparations has been approved by more and more clinicians and patients because it can reduce the number of injections and improve patient compliance.Various GLP-1 RA weekly preparations have undergone a series of clinical trials in China and have gradually entered the market.Currently,the GLP-1 RA weekly preparations marketed in China mainly include exenatide microspheres for injection,dulaglutide and polyethylene glycol loxenatide(PEX168).This article will be dedicated to assessing the efficacy and safety of the above three GLP-1 RA weekly preparations in China.

关 键 词：GLP-1 RA周制剂 疗效 安全性 糖尿病 2型 中国人群 

分 类 号：R587.1[医药卫生—内分泌]